Pharmafile Logo

skin check

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Dermatological diseases are estimated to affect 1.8 billion people worldwide

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases

The collaboration will aim to find new therapies for dermatological diseases through AI

- PMLiVE

AstraZeneca and generative AI company Absci enter $247m oncology partnership

The collaboration is aimed at developing an AI-designed antibody drug for an oncology target

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the...

Impetus Digital

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

Can Cinderella save us?

Study finds AI detects AMR faster than gold-standard testing

The method detected AMR with at least 80% accuracy on a per-cell basis, within 30 minutes

Ease and Effectiveness of Knowledge Sharing; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #8. The Ease and Effectiveness of Sharing Knowledge and Data...

Impetus Digital

- PMLiVE

AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials

Evinova aims to meet the needs of patients, healthcare professionals and regulators

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links